Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $51,030.

  • Addex Therapeutics' Share-based Compensation fell 100.00% to $51,030 in Q2 2025 from the same period last year, while for Jun 2025 it was -$528.9 billion, marking a year-over-year increase of 66.32%. This contributed to the annual value of $571,720 for FY2024, which is 71.39% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Share-based Compensation is $51,030, which was up 100.00% from -$538.5 billion recorded in Q4 2024.
  • In the past 5 years, Addex Therapeutics' Share-based Compensation ranged from a high of $769.3 billion in Q3 2022 and a low of -$1,584.2 billion during Q4 2023.
  • In the last 3 years, Addex Therapeutics' Share-based Compensation had a median value of $396,271 in 2023 and averaged -$233.8 billion.
  • As far as peak fluctuations go, Addex Therapeutics' Share-based Compensation plummeted by 222,878,698.23% in 2023, and later surged by 1,120,911.59% in 2024.
  • Over the past 4 years, Addex Therapeutics' Share-based Compensation (Quarterly) stood at $710,802 in 2022, then tumbled by 222,878,698.23% to -$1,584.2 billion in 2023, then surged by 66.01% to -$538.5 billion in 2024, then crashed by 100.00% to $51,030 in 2025.
  • Its last three reported values are $51,030 in Q2 2025, -$538.5 billion for Q4 2024, and $4.4 billion during Q3 2024.